Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 3, 2005, Pages 908-915

  Berry, Valerie ^a   Hoover, Jennifer ^a   Singley, Christine ^a   Woodnutt, Gary ^a,b  

^a GLAXOSMITHKLINE   (United States)

^b DIVERSA CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAMASE; CLAVULANATE POTASSIUM; LEVOFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE CALCULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; SUSTAINED RELEASE PREPARATION;

AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANIMALS; AZITHROMYCIN; CLAVULANIC ACID; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; RATS; RATS, SPRAGUE-DAWLEY; STREPTOCOCCUS PNEUMONIAE;

EID: 14744279816     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.3.908-915.2005     Document Type: Article

References (31)

1. Alder, J. D., P. J. Ewing, A. M. Nilius, M. Mitten, A. Tovcimak, A. Oleksijew, K. Jarvis, L. Paige, and S. K. T. Tanaka. 1998. Dynamics of clarithromycin and azithromycin efficacies against experimental Haemophilus influenzae pulmonary infection. Antimicrob. Agents Chemother. 42:2385-2390.
2. Berry, V., C. E. Thorburn, S. J. Knott, and G. Woodnutt. 1998. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae. Antimicrob. Agents Chemother. 42:3193-3199.
3. Berry, V., R. Page, J. Satterfield, C. Singley, R. Straub, and G. Woodnutt. 2000. Comparative in vivo activity of gemifloxacin in a rat model of respiratory tract infection. J. Antimicrob. Chemother. 45(Suppl. 1):79-85.
4. Chien, S.-C., M. C. Rogge, L. G. Gisclon, C. Curtin, F. Wong, J. Natarajan, R. R. Williams, C. L. Fowler, W. K. Cheung, and A. T. Chow. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral and intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260.
5. Cooper, C. E., B. Slocombe, and A. R. White. 1990. Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against β-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae. J. Antimicrob. Chemother. 26:371-380.
6. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
7. Davidson, R., R. Cavalcanti, J. L. Brunton, D. J. Bast, J. C. de Azavedo, P. Kibsey, C. Fleming, and D. E. Low. 2002. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N. Engl. J. Med. 346:747-750.
8. Empey, P. E., H. R. Jennings, A. C. Thornton, R. P. Rapp, and M. E. Evans. 2001. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann. Pharmacother. 35:687-690.
9. Foulds, G., R. M. Shepard, and R. B. Johnson. 1990. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 25:73-82.
10. Garau, J., M. R. Jacobs, B. Wynne, E. Berkowitz, and M. Tvvynholm. 2003. Pharmacokinetically enhanced amoxicillin/clavulanate (AMX/CA) 2,000/125 mg in the treatment of community-acquired pneumonia and acute bacterial sinusitis (ABS) caused by Streptococcus pneumonias, abstr. L-1382, p. 422. In Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Hoberman, A., R. Dagan, A. Rosenblut, E. Leibovitz, A. Huff, and B. Wynne. 2003. Extra-strength amoxicillin-clavulanate (A/C-ES) versus azithromycin (AZI) for acute otitis media (AOM) in children, abstr. G-459, p. 279. In Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Huff, J., A. White, E. Power, J. Weil, and G. R. Mera. 2002. 10-year trends in penicillin- and erythromycin-resistant Streptococcus pneumonias for 5 European countries and the USA: the Alexander Project, abstr. C2-1624, p. 108. In Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Jackson, D., D. L. Cooper, R. Horton, P. F. Langley, D. H. Staniforth, and J. A. Sutton. 1983. Absorption pharmacokinetic and metabolic studies with augmentin, p. 88-101. In E. A. P. Croydon and M. F. Michel (ed.), Augmentin: clavulanate-potentiated amoxicillin. Proceedings of the European Symposium, June 1982. Excerpta Medica, Scheveningen, The Netherlands.
14. Jacobs, M. R. 2003. How can we predict bacterial eradication? Int. J. Infect. Dis. 7(Suppl. 1):S13-S20.
15. Jacobs, M. R., D. Felmingham, P. C. Appelbaum, and R. N. Grüneberg. 2003. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J. Antimicrob. Chemother. 52:229-246.
16. Johnson, D. M., H. S. Sader, T. R. Fritsche, D. J. Biedenbach, and R. N. Jones. 2003. Susceptibility trends of Haemophilus influenzae and Moraxella catarrhalis against orally administered antimicrobial agents: five-year report from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 47:373-376.
17. Jones, M., R. Blosser-Middleton, I. Critchley, J. Karlowsky, C. Thornsberry, and D. Sahm. 2003. In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. Clin. Microbiol. Infect. 9:590-599.
18. Kaye, C. M., A. Allen, S. Perry, M. McDonagh, M. Davy, K. Storm, N. Bird, and O. Dewit. 2001. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin. Ther. 23:578-584.
19. Kays, M. B., D. W. Smith, M. E. Wack, and G. A. Denys. 2002. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 22:395-399.
20. Lonks, J. R., J. Garau, L. Gomez, M. Xercavins, A. Ochoa de Echaguen, I. F. Gareen, P. T. Reiss, and A. A. Medeiros. 2002. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin. Infect. Dis. 35:556-564.
21. MacGowan, A. P. 2004. Elements of design: the knowledge on which we build. Clin. Microbiol. Infect. 10(Suppl. 2):6-11.
22. Mitten, M. J., J. Meulbroek, M. Nukkala, L. Paige, K. Jarvis, A. Oleksijew, A. Tovcimak, L. Hemandez, J. D. Alder, P. Ewing, Y. S. Or, Z. Ma, A. M. Nilius, K. Mollison, and R. K. Flamm. 2001. Efficacies of ABT-773, a new ketolide, against experimental bacterial infections. Antimicrob. Agents Chemother. 45:2585-2593.
23. National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobial susceptibility testing, document M100-S10, 10th informational supplement. National Committee for Clinical Laboratory Standards, Wayne, Pa.
24. National Committee for Clinical Laboratory Standards. 2003. Performance standards for antimicrobial susceptibility testing, doc. M100-S13, 13th informational supplement. National Committee for Clinical Laboratory Standards, Wayne, Pa.
25. Peric, M., B. Bozdogan, M. R. Jacobs, and P. C. Appelbaum. 2003. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob. Agents Chemother. 47:1017-1022.
26. Waites, K., and S. Brown. 2003. Antimicrobial resistance among isolates of respiratory tract infection pathogens from the southern United States: data from the PROTEKT US surveillance program 2000/2001. South. Med. J. 96:974-985.
27. White, A. R., C. Kaye, J. A. Poupard, R. Pypstra, G. Woodnutt, and B. Wynne. 2004. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J. Antimicrob. Chemother. 53(Suppl. 1):I3-I20.
28. Woodnutt, G. 2000. Pharmacodynamics to combat resistance. J. Antimicrob. Chemother. 46(Suppl. T1):25-31.
29. Woodnutt, G., and V. Berry. 1999. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:35-40.
30. Woodnutt, G., and V. Berry. 1999. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory infections caused by strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:29-34.
31. Woodnutt, G., V. Berry, and J. Bryant. 1996. Evaluation of reduced dosing schedule of amoxicillin (AMX) using two pharmacodynamic models, abstr. A40, p. 8. In 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.